Drug Trial Radar · NCT01472016
Study of ABT-700 in Subjects With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Oct 6, 2011
Primary completion
Apr 27, 2017
Study completion Apr 27, 2017
Sponsor
- Lead sponsor
- AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 16, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET amplification or c-Met overexpression. ABT-700, previously known as h224G11 in publications, is an anti-c-Met antibody. The early clinical development plan for ABT-700 is based on the activity demonstrated in preclinical models. Up to 124 subjects will be enrolled.
Conditions
- Advanced Solid Tumors
Interventions
ABT-700Drug
ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
docetaxelDrug
Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
FOLFIRIDrug
5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
cetuximabDrug
Cetuximab will be administered by intravenous infusion weekly.
erlotinibDrug
Erlotinib will be taken orally daily.
ABT-700Drug
ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinibTime frame: First cycle of treatment through 60 day follow-up visit
- To Evaluate the pharmacokinetics of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinibTime frame: At each cycle of treatment through 60 days after last dose.
- To determine the recommended Phase 2 dose for ABT-700Time frame: First cycle of treatment through 60 day follow-up visit
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.